Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease

Journal of Anatomy

Volumn 196, Issue 4, 2000, Pages 597-607

  Besret, Laurent ^b   Kendall, A Lisa ^b   Dunnett, Stephen B ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Huntington's disease; PET imaging; Striatal transplantation

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DESIPRAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOXETINE; HALOPERIDOL; LIGAND; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BINDING SITE; BRAIN TRANSPLANTATION; CAUDATE NUCLEUS; CLINICAL PROTOCOL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; GRAFT SURVIVAL; HUNTINGTON CHOREA; LIGAND BINDING; MONKEY; NEOSTRIATUM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR BINDING; RECEPTOR OCCUPANCY; REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALLITHRIX; GRAFT SURVIVAL; HUMANS; HUNTINGTON DISEASE; LIGANDS; MAGNETIC RESONANCE IMAGING; NEOSTRIATUM; RATS; RECEPTORS, DOPAMINE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033925126     PISSN: 00218782     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0021878299005932     Document Type: Review

References (66)

1. 2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology 140, 470-477.
2. 2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119, 2085-2095.
3. 11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Annals of Neurology 43, 253-255.
4. ARNT J, SKARFELDT T (1998) Do novel anti-psychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18, 63-101.
5. BACHOUD-LÉVY AC, HANTRAYE P, PESCHANSKI M (1998) Prospectives for cell and gene therapy in Huntington's disease. Progress in Brain Research 117, 511-524.
6. BACKMAN L, ROBINS-WAHLIN TB, LUNDIN A, GINOVART N, FARDE L (1997) Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 120, 2207-2217.
7. BARTENSTEIN P, WEINDL A, SPIEGEL S, BOECKER H, WENZEL R, CEBALLOS-BAUMANN AO et al. (1997) Central motor processing in Huntington's disease. A PET study. Brain 120, 1553-1567.
8. BESRET L, PAGE KJ, DUNNETT SB (2000) The problem of antipsychotic treatment for functional imaging in Huntington's disease: receptor binding, gene expression and locomotor activity after subchronic administration and washout of haloperidol in the rat. Brain Research, in press.
9. BJÖRKLUND A, CAMPBELL K, SIRINATHSINGHJI DJS, FRICKER RA, DUNNETT SB (1994) Functional capacity of striatal transplants in the rat Huntington model. In Functional Neural Transplantation (ed. Dunnett SB, Björklund A), pp. 157-195. New York: Raven Press.
10. BROWNEEL AL, LIVNI E, GALPERN W, ISACSON O (1998) In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Annals of Neurology 43, 387-390.
11. 2 receptors in Huntington's disease. European Journal of Pharmacology 88, 223-229.
12. 2 receptor SPECT before and after antidepressant therapy. Psychopharmacology 126, 91-94.
13. 11C]raclopride. Archives of General Psychiatry 47, 213-219.
14. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry 49, 538-544.
15. 3H]forskolin binding. Experimental Neurology 110, 219-227.
16. FLORIJN WJ, TARAZI FI, CREESE I (1997) Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. Journal of Pharmacology and Experimental Therapeutics 280, 561-569.
17. FRICKER RA, TORRES EM, HUME SP, MYERS R, OPACKA-JUFFREY J, ASHWORTH S et al. (1997) The effects of donor stage on the survival and function of embryonic striatal grafts in the adult rat brain. II. Correlation between positron emission tomography and reaching behaviour. Neuroscience 79, 711-721.
18. FRICKER RA, TORRES EM, HUME SP, MYERS R, OPACKA-JEFFRREY J, ASHWORTH S et al. (1997) The effects of donor stage on the survival and function of embryonic striatal grafts. II. Correlation between positron emission tomography and reaching behaviour. Neuroscience 79, 711-722.
19. GINOVART N, LUNDIN A, FARDE L, HALLDIN C, BACKMAN L, SWAHN CG et al. (1997) PET study of the pre-and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 120, 503-514.
20. GRAFTON ST, MAZZIOTTA JC, PAHL JJ, ST GEORGE-HYSLOP P, HAINES JL, GUSELLA J et al. (1992) Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Archives of Neurology 49, 1161-1167.
21. HAHN-BARMA V, DEWEER B, DURR A, DODE C, FEINGOLD J, PILLON B et al. (1998) Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. Journal of Neurology Neurosurgery and Psychiatry 64, 172-177.
22. HARPER PS (1996) Huntington's Disease, 2nd edn. London: W. B. Saunders.
23. HAYDEN MR, MARTIN WRW, STOESSL AJ, CLARK C, HOLLENBERG S, ADAM MJ et al. (1986) Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 36, 888-894.
24. 2 receptors: homogenate binding and autoradiographic studies. Neurochemistry International 30, 277-290.
25. HUME SP, MYERS R, BLOOMFIELD PM, OPACKA-JUFFRY J, CREMER JE, AHIER RG et al. (1992) Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse 12, 47-54.
26. HUME SP, LAMMERTSMA AA, MYERS RA, RAJESWARAN S, BLOOMFIELD PM, ASHWORTH A et al. (1996) The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. Journal of Neuroscience Methods 67, 103-112.
27. JONES T (1996a) The role of positron emission tomography within the spectrum of medical imaging. European Journal of Nuclear Medicine 23, 207-211.
28. JONES T (1996b) The imaging science of positron emission tomography. European Journal of Nuclear Medicine 23, 807-813.
29. 2 receptors in human striatum receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 2, 546-557.
30. KAPUR S (1998) A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Molecular Biology 3, 135-140.
31. KENDALL AL, RAYMENT FD, TORRES EM, BAKER HF, RIDLEY RM, DUNNETT SB (1998a) Functional integration of striatal allografts in a primate model of Huntington's disease. Nature Medicine 4, 727-729.
32. KENDALL AL, RAYMENT D, AIGBIRHIO F, BAKER HF, CHANDLER R, CLARK J et al. (1998b) In vivo PET analysis of the status of striatal allografts in the common marmoset. European Journal of Neuroscience 10, suppl, 370
33. 3H]SCH23390 binding sites in the rat striatum and limbic system. European Journal of Pharmacology 139, 163-169.
34. KOPYOV OV, JACQUES S, LIEBERMAN A, DUMA CM, EAGLE KS (1998a) Safety of intrastriatal neurotransplantation for Huntington's disease patients. Experimental Neurology 119, 97-108.
35. KOPYOV OV, JACQUES S, KURTH M, PHILPOTT LM, LEE A, PATTERSON M et al. (1998b) Fetal transplantation for Huntington's disease: clinical studies. In Cell Transplantation for Neurological Disorders (ed. Freeman TB, Kordower JH), pp. 95-134. Totowa, NJ: Humana Press.
36. KORDOWER JH, FREEMAN TB, SNOW BJ, VINGERHOETS FG, MUFSON EJ, SANBERG PR et al. (1995) Long-term fetal nigral graft survival and putamenal innervation correlates with functional recovery in a patient with Parkinsons disease - a clinical-pathological analysis. Experimental Neurology 135, 166-166.
37. KUHL DE, METTER EJ, RIEGE WH, MARKHAM CH (1984) Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. Annals of Neurology 15, S119-S125.
38. LANGSTON JW, WIDNER H, GOETZ CG (1992) Core assessment program for intracerebral transplantation (CAPIT). Movement Disorders 7, 2-13.
39. 2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Research 575, 47-56.
40. LINDVALL O (1991) Prospects of transplantation in human neurodegenerative diseases. Trends in Neurosciences 14, 376-384.
41. LINDVALL O (1997) Neural transplantation: a hope for patients with Parkinson's disease? Neuro Report 8(14), iii-x.
42. LINDVALL O, BRUNDIN P, WIDNER H, REHNCRONA S, GUSTAVII B, FRACKOWIAK R et al. (1990) Grafts of fetal dopamine neurones survive and improve motor function in Parkinson's disease. Science 247, 574-577.
43. MADRAZO I, FRANCO-BOURLAND RE, CASTREJON H, CUEVAS C, OSTROSKY-SOLIS F (1995) Fetal striatal homotransplantation for Huntington's disease: first two case reports. Neurological Researeh 17, 312-315.
44. MARTIN WRW, CLARK C, AMMANN W, STOESSL AJ, SHTYBEL W, HAYDEN MR (1992) Cortical glucose metabolism in Huntington's disease. Neurology 42, 223-229.
45. 2 dopamine receptor availability after discontinuation of haloperidol decanoate. Archives of General Psychiatry 54, 953-958.
46. OLANOW CW, KORDOWER JH, FREEMAN TB (1996) Fetal nigral transplantation as a therapy for Parkinson's disease. Trends in Neuroscience 19, 102-109.
47. OLANOW CW, FREEMAN TB, KORDOWER JH (1997) Neural transplantation as a therapy for Parkinson's disease. Advances in Neurology 74, 249-269.
48. PALFI S, NGUYEN JP, BRUGIERES P, LEGUERINEL C, HANTRAYE P, RÉMY P et al. (1998) MRI-stereotactical approach for neural grafting in basal ganglia disorders. Experimental Neurology 150, 272-281.
49. PESCHANSKI M, CESARO P, HANTRAYE P (1995) Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 68, 273-285.
50. PHILPOTT LM, KOPYOV OV, LEE AJ, JACQUES S, DUMA CM, CAINE S et al. (1997) Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplantation 6, 203-212.
51. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340, 199-202.
52. QUINN N, BROWN R, CRAUFURD D, GOLDMAN S, HODGES J, KIEBURTZ K et al. (1996) Core assessment program for intracerebral transplantation in Huntington's disease (CAPIT-HD). Movement Disorders 11, 143-150.
53. QUINN NP, BROWN R, CRAUFURD D, GOLDMAN S, HODGES JR, KIEBURTZ K et al. (1996) Core assessment program for intracerebral transplantation in Huntington's disease (CAPIT-HD). Movement Disorders 11, 143-150.
54. RAJESWARAN S, BAILEY DL, HUME SP, TOWNSEND DW, GEISSBUHLER A, YOUNG J et al. (1992) 2-D and 3-D imaging of small animals and the human radial artery with a high-resolution detector for PET. IEEE Transactions on Medical Imaging 11, 386-391.
55. RICHFIELD EK, O'BRIEN CF, ESKIN T, SHOULSON I (1991) Heterogeneous dopamine receptor changes in early and late Huntington's disease. Life Sciences 132, 121-126.
56. ROSS BD, DUBOWITZ DJ, HOANG T, BLUML S, KOPYOV OV, JACQUES DS (1997) Quantitative 1H MRS of neurotransplantation in patients with Parkinson's and Huntington's disease. Radiology 205, 759-759.
57. SANBERG PR, BORLONGAN CV, WICTORIN K, ISACSON O (1998) Fetal tissue transplantation for Huntington's disease: preclinical studies. In Cell Transplantation for Neurological Disorders (ed. Freeman TB, Kordower JH), pp. 77-93. Totowa, NJ: Humana Press.
58. 1 receptors after long-term haloperidol treatment: lack of correspondence with the development of vacuous chewing movements. Behavioral Brain Research 90, 125-132.
59. SAWLE GV, MYERS R (1993) The role of positron emission tomography in the assessment of human neurotransplantation. Trends in Neurosciences 16, 172-176.
60. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1, 5-15.
61. SHANNON KM, KORDOWER JH (1996) Neural transplantation for Huntington's disease: experimental rationale and recommendations for clinical trials. Cell Transplantation 5, 339-352.
62. SRAMKA M, RATTAJ M, MOLINA H, VOJTASSAK J, BELAN V, RUZICKY E (1992) Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea. Streotactic and Functional Neurosurgery 58, 79-83.
63. TARAZI FI, FLORIJN WJ, CREESE I (1997) Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscicnce 78, 985-996.
64. TORRES EM, FRICKER RA, HUME S, MYERS R, OPACKA-JUFFRY J, ASHWORTH S (1995) Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. Neuro Report 6, 2017-2021.
65. 2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 118, 689-696.
66. WENNING GK, ODIN P, MORRISH P, REHNCRONA S, WIDNER H, BRUNDIN P et al. (1997) Short-and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology 42, 95-107.